Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis — Stella
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(33 sites)
United States
Local Institution - 0114, Loma Linda, California
University of California Davis Health, Sacramento, California
University of South Florida, Tampa, Florida
Local Institution - 0093, Chicago, Illinois
University of Chicago Medical Center, Chicago, Illinois
Local Institution - 0047, Louisville, Kentucky
Local Institution - 0131, New Brunswick, New Jersey
Local Institution - 0132, Teaneck, New Jersey
Local Institution - 0091, Cincinnati, Ohio
Local Institution - 0092, Portland, Oregon
Local Institution - 0133, El Paso, Texas
Medical College of Wisconsin, Milwaukee, Wisconsin
Australia
Royal Children's Hospital, Melbourne, Victoria
Italy
University of Naples Federico II, Naples, Campania
Ospedale San Raffaele, Milan, Lombardy
Local Institution - 0081, Milan, Lombardy
Neurological Center Of Latium, Rome, Roma
Mexico
Local Institution - 0078, Mexico City, DIF
Poland
Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan, Greater Poland Voivodeship
Portugal
2Ca Braga, Braga
Unidade Local de Saúde de Coimbra, E.P.E., Coimbra
Centro Hospitalar de Lisboa Central, Lisbon
Local Institution - 0102, Porto
Puerto Rico
Local Institution - 0134, Caguas
Romania
Spitalul Clinic de Copii Doctor Victor Gomoiu, Bucharest, Bucharest
Prof. Dr. Alexandru Obregia Psychiatry Hospital, Bucharest, Bucharest
Spain
Local Institution - 0096, Esplugues de Llobregat, Barcelona [Barcelona]